{"id":"W4284884980","doi":"10.1016/j.ejca.2022.05.023","title":"Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company; Ono Pharmaceutical; Ignyta; Chugai Pharmaceutical; EMD Serono; Genentech; Daiichi Sankyo Europe; Servier; Sanofi; Kyowa Hakko Kirin; Eisai; Puma Biotechnology; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Mirati Therapeutics; National Medical Research Council; Kissei; GlaxoSmithKline; Novartis Institutes for BioMedical Research; Amgen; Dainippon Sumitomo Pharma; Pfizer; Novartis Pharmaceuticals Corporation; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Rash; Internal medicine; Adverse effect; Clinical endpoint; Maculopapular rash; Discontinuation; Brain metastasis; Lung cancer; Response Evaluation Criteria in Solid Tumors; Oncology; Gastroenterology; Phases of clinical research; T790M; non-small cell lung cancer (NSCLC); Cancer; Surgery; Toxicity; Epidermal growth factor receptor; Metastasis; Gefitinib; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001939438,0.002042822,0.003027059,0.0003547469,0.0004161359,0.001526255,0.0008296635,0.001614551,0.002693949],"category_scores_gemma":[0.001021031,0.000625801,0.002333304,0.0003720536,0.0009742777,0.001576244,0.0002497116,0.002755343,0.0009482012],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001084869,"about_ca_system_score_gemma":0.001314627,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001290235,"about_ca_topic_score_gemma":0.004235622,"domain_scores_codex":[0.9994612,0.0002240386,0.00002883569,0.00008474084,0.00006452095,0.000136602],"domain_scores_gemma":[0.999369,0.0001394107,0.0001489365,0.00007139552,0.00005760677,0.0002137251],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8591506,0.02552348,0.003793543,0.001154701,0.002564293,0.0001588812,0.0002020149,0.002183918,0.02613065,0.0002639901,0.002967719,0.07590635],"study_design_scores_gemma":[0.7632445,0.2140918,0.01360522,0.00006355876,0.001582477,0.0002889459,0.0001022979,0.001598883,0.002334892,0.0003265199,0.002688309,0.0000725596],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920149,0.003188124,0.0004807408,0.0004441771,0.0001776775,0.00101149,0.001234228,0.0000878278,0.00136086],"genre_scores_gemma":[0.9853938,0.004120705,0.001453623,0.0009917975,0.0002246533,0.001280423,0.002861584,0.00005605305,0.003617409],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003027059,"threshold_uncertainty_score":0.01025683,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06437095391339918,"score_gpt":0.3997258231664293,"score_spread":0.3353548692530301,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}